Edition:
United Kingdom

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

52.43USD
15 Dec 2017
Change (% chg)

$0.87 (+1.69%)
Prev Close
$51.56
Open
$52.06
Day's High
$52.95
Day's Low
$51.13
Volume
904,527
Avg. Vol
415,464
52-wk High
$65.51
52-wk Low
$37.27

Latest Key Developments (Source: Significant Developments)

Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE.IONIS PHARMA SAYS ROCHE HAS EXERCISED OPTION TO LICENSE IONIS-HTT(RX).IONIS PHARMACEUTICALS INC - ROCHE WILL NOW BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIAL ACTIVITIES FOR IONIS-HTT(RX).IONIS PHARMACEUTICALS INC - IN CONJUNCTION WITH DECISION TO LICENSE IONIS-HTT(RX), IONIS EARNED A $45 MILLION LICENSE FEE FROM ROCHE..  Full Article

Ionis eligible to get nearly $800 mln in milestones from deal with Janssen
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Ionis Pharmaceuticals Inc -:Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen.Ionis Pharmaceuticals - licensed second orally delivered generation 2.5 antisense drug to Janssen Biotech, Inc. for which Ionis earned $5 million​.Ionis Pharmaceuticals -Janssen to now assume all global development, regulatory, commercialization responsibilities for IONIS-JBI2-2.5(RX )for GI diseases​.Ionis Pharma- ‍under global collaboration deal with Janssen, co eligible to receive nearly $800 million in regulatory, sales milestone payments, others.Ionis Pharma- ‍in addition, will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized​.Ionis Pharmaceuticals Inc - ‍IONIS-JBI1-2.5(RX), first collaboration target, was licensed to Janssen last year.  Full Article

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Ionis Pharma, ‍Dynacure announces Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Ionis Pharmaceuticals Inc :Ionis Pharmaceuticals Inc - co, ‍Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​.Ionis Pharmaceuticals Inc - ‍Dynacure will now assume all development and commercialization responsibilities for program​.Ionis Pharmaceuticals Inc - ‍Ionis is eligible to receive additional cash or equity of up to more than $205 million in milestone payments​.Ionis Pharmaceuticals Inc - ‍Ionis is eligible to receive royalties on future product sales of drug under this collaboration​.  Full Article

Ionis Pharmaceuticals reports Q3 earnings per share $0.00
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Ionis Pharmaceuticals Inc :Ionis Pharmaceuticals reports financial results and highlights for third quarter 2017.Q3 earnings per share $0.00.Q3 earnings per share view $0.01 -- Thomson Reuters I/B/E/S.Ionis Pharmaceuticals Inc - ‍on track to meet its 2017 guidance​.Ionis Pharmaceuticals Inc - ‍qtrly revenue $120.9 million versus $110.9 million.Ionis Pharmaceuticals Inc - ‍projecting an increase in operating expenses for Q4 of 2017 compared to Q3 of 2017​.Q3 revenue view $117.0 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $-0.16, revenue view $438.8 million -- Thomson Reuters I/B/E/S.  Full Article

IONIS PHARMACEUTICALS TO COLLABORATE WITH SEVENTH SENSE BIOSYSTEMS
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS ENTERS INTO COLLABORATION WITH SEVENTH SENSE BIOSYSTEMS TO SUPPORT DEVELOPMENT OF IMPROVED BLOOD COLLECTION AND DIAGNOSTIC DEVICE.IONIS PHARMACEUTICALS INC - ‍AS PART OF ITS COMMITMENT TO COLLABORATION, CO MADE INVESTMENT OF $2 MILLION IN 7SBIO AS PART OF A SERIES C FINANCING​.  Full Article

IONIS PHARMACEUTICALS INITIATES IONIS-MAPT RX STUDY IN PATIENTS WITH ALZHEIMER'S DISEASE
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS INITIATES CLINICAL STUDY OF IONIS-MAPT RX IN PATIENTS WITH ALZHEIMER'S DISEASE.IONIS PHARMACEUTICALS INC - ‍IONIS EARNS $10 MILLION MILESTONE PAYMENT FROM BIOGEN​.  Full Article

Ionis earns $75 mln from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx
Tuesday, 14 Feb 2017 

Ionis Pharmaceuticals Inc - : Ionis earns $75 million from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx .Co to also initiate development of IONIS-FXI-L(Rx), which uses Ionis' proprietary ligand conjugated antisense, or LICA, technology.  Full Article

Biogen completes submission of new drug application
Monday, 26 Sep 2016 

Biogen Inc : Biogen completes rolling submission of new drug application to FDA for nusinersen as a treatment for spinal muscular atrophy . Biogen completes rolling submission of new drug application to FDA for nusinersen as a treatment for spinal muscular atrophy . Submission of marketing authorization application to European medicines agency planned in coming weeks .Has also applied for priority review for nusinersen.  Full Article

Ionis Pharmaceuticals reports Q2 loss per share $0.47
Tuesday, 9 Aug 2016 

Ionis Pharmaceuticals Inc : Ionis pharmaceuticals reports financial results and highlights for second quarter 2016 . Q2 loss per share $0.47 .Qtrly revenue $38.5 million versus $120.4 million.  Full Article

Photo

'Ground-breaking' new drug gives hope in Huntington's disease

LONDON Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.